ERBB2 and kidney neoplasm: Due to its rarity, mCDC has often been excluded from randomized phase II-III trials evaluating targeted therapies in kidney neoplasms and until recently clinical evidence of activity of TKIs (such as sorafenib, cabozantinib, sunitinib, pazopanib) or other targeted agents (mTOR-inhibitors and anti-Her2 agents) were mostly limited to case reports or retrospective series [75,76,77,78].